Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast

The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios) are entrenched in the treatment of HR-positive / HER2-negative disease, a trend that will continue through 2032. Current treatment options for HER2-positive breast cancer have expanded, owing to the launch of novel HER2-targeting agents (Daiichi Sankyo / AstraZeneca’s Enhertu, Seagen / Pfizer’s Tukysa, and MacroGenics’ Margenza), sales of which will offset the entry of generics and biosimilars. In triple-negative breast cancer, the approvals of PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza, Pfizer’s Talzenna), immune checkpoint inhibitors (Merck & Co.’s Keytruda), and TROP2-targeted agents (Gilead’s Trodelvy) are diversifying therapy options for patients. Enhertu’s approval in 2022 for HER2-low disease, a new subset of breast cancer, will further reshape the treatment landscape.


  • What is the size of clinically and commercially relevant drug-treatable breast cancer populations, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent drug approvals, such as Trodelvy, Keytruda, Piqray, Enhertu, and Orserdu, on the various subpopulations of breast cancer?
  • Which are the most promising agents in the pipeline, and how will they shape the future of the breast cancer therapy market?
  • Which key drivers and constraints will affect the breast cancer therapy market over the forecast period?


  • Geographies: United States, EU5, Japan.
  • Primary research: 18 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other Clarivate research.
  • Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy.
  • Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2032, segmented by brands / biosimilars / generics and market-relevant drug-treatable populations.
  • Emerging therapies: Phase 3/PR: 20 drugs; coverage of select Phase 1 and 2 products.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports